Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study.
Oh SY, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Kang HJ, Choi CW, Park J, Kim HJ, Kwon JH, Lee HS, Lee GW, Eom HS, Kwak JY, Suh C, Kim HJ.
Oh SY, et al. Among authors: eom hs.
Cancer Sci. 2010 Nov;101(11):2443-7. doi: 10.1111/j.1349-7006.2010.01698.x.
Cancer Sci. 2010.
PMID: 20831770
Free PMC article.